Disease Risk Factor Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Disease Risk Factor Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Australian Cancer Technology
U.S. biotech executive Arthur J. Benvenuto appointed to Australian cancer board
October 17th, 2004
The board of biotechnology company Australian Cancer Technology (ACU) has appointed U.S. biotechnology executive Arthur J. Benvenuto as a non-executive director of the company. Benvenuto is president of Healthcare Strategies, LLC, a specialist life sciences consultancy. He was formerly chairman and CEO of Advanced Tissue Sciences, Inc. (now part of Smith and Nephew) and prior to that held senior executive positions with Eli Lilly, including president and general manager of Eli Lilly Canada, Inc. He has sat on many biotechnology board and directed public and private companies and institutions. Australian Cancer's U.S. activities include the revisys...
Source: Disease Risk Factor Week (2004-10-17)
|
